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Abstract
Background: While cannabinoids have been shown to ameliorate liver fibrosis, their effects in chronic pancreatitis and on
pancreatic stellate cells (PSC) are unknown.
Methodology/Principal Findings: The activity of the endocannabinoid system was evaluated in human chronic pancreatitis
(CP) tissues. In vitro, effects of blockade and activation of cannabinoid receptors on pancreatic stellate cells were
characterized. In CP, cannabinoid receptors were detected predominantly in areas with inflammatory changes, stellate cells
and nerves. Levels of endocannabinoids were decreased compared with normal pancreas. Cannabinoid-receptor-1
antagonism effectuated a small PSC phenotype and a trend toward increased invasiveness. Activation of cannabinoid
receptors, however, induced de-activation of PSC and dose-dependently inhibited growth and decreased IL-6 and MCP-1
secretion as well as fibronectin, collagen1 and alphaSMA levels. De-activation of PSC was partially reversible using a
combination of cannabinoid-receptor-1 and -2 antagonists. Concomitantly, cannabinoid receptor activation specifically
decreased invasiveness of PSC, MMP-2 secretion and led to changes in PSC phenotype accompanied by a reduction of
intracellular stress fibres.
Conclusions/Significance: Augmentation of the endocannabinoid system via exogenously administered cannabinoid
receptor agonists specifically induces a functionally and metabolically quiescent pancreatic stellate cell phenotype and may
thus constitute an option to treat inflammation and fibrosis in chronic pancreatitis.
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Introduction
The management of chronic pancreatitis still remains a clinical
challenge, with no definite medical cure and only symptomatic
treatment available for this disease[1–3]. In some cases, surgical
resection of the inflammatory mass (usually localized in the
pancreatic head) may permanently relieve symptoms[4]. Histo-
logically, areas of fibrosis (deposits of extracellular matrix (ECM)
proteins) are found which may contain clusters of mononuclear
cell infiltration[5–7]. Enlarged nerves may be invaded by
mononuclear cells, potentially leading to neural damage, which
may in part explain the severe pain syndrome[8,9]. As a
consequence, endocrine and exocrine functions of the pancreas
are progressively lost, ultimately resulting in a scarred pancreas
without its physiological functions.
In the past years, pancreatic stellate cells (activated myofibro-
blasts; PSC) have been identified as major determinants of
pancreatic fibrosis: they have been shown to be the major source
of extracellular matrix production[10,11] and to stringently control
the balance of ECM secretion and digestion by producing matrix
metalloproteinases and their corresponding inhibitors[12]. PSC also
modulate the local immune reaction by production and secretion of
cytokines and chemokines as well as by their phagocytic activity[13–
17]. However, the pathobiology of pancreatic fibrogenesis/inflam-
mation and the interplay between stellate cells[18–20], immune cells
and nerves is poorly understood, and currently no potentially
curative medical treatment is available.
Comparable with liver cirrhosis, prevention of loss of functional
pancreatic parenchyma by controlling and resolving the overt
scarring reaction to an inflammatory stimulus may constitute a
therapeutic approach. Although a number of substances have been
identified so far which were initially promising in ameliorating or
even reversing the disease, none of these was clinically proven to
exert such beneficial properties[21–23].
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exogenously administered cannabinoids, the endocannabinoid
system (ECS) and its changes in pathological states have recently
attracted considerable attention[24,25]. Particularly, cannabinoids’
immune-modulatory function and their influence on lymphocytes
constitute a basis for their use in a wide variety of inflammatory
diseases[26–30]. Besides these well-studied effects, (endo-)cannabi-
noids have recently been shown to influence liver fibrogenesis
through various mechanisms. Siegmund and co-workers[31,32]
have shown that the endocannabinoid anandamide induces necrosis
in hepatic stellate cells independent of CB1 and CB2 receptors. In
contrast to these results, Julien et al.[33] have found in experimen-
tally induced liver cirrhosis that an activation of the CB2 receptor on
hepatic stellate cells leads to apoptosis and attenuated liver fibrosis
progression. Teixeira-Clerk and co-authors[34] have proposed CB1
antagonism as a new strategy to treat liver fibrosis. Altogether, these
results point towards a potential use of cannabinoids as substances to
ameliorate or even revert liver fibrogenesis. However, the exact
mechanism of how (and particularly in which disease stage) either
CB receptor activation or antagonism may be useful in attenuating
chronic liver cirrhosis remains to be determined.
In chronic pancreatitis, activity of the endocannabinoid system
and effects of exogenously administered cannabinoids have not
been analyzed so far. In this study, we evaluated levels of
endocannabinoids and their receptors as well as the potential
function of cannabinoid activation and antagonism by synthetic
cannabinoid derivatives and their respective antagonists in human
chronic pancreatitis tissues and CP-derived PSC.
Materials and Methods
Patients and tissue collection
Pancreas tissues were obtained intraoperatively from patients
undergoing resection for chronic pancreatitis (21 men, 19 women).
Normal pancreas tissue samples were collected within the organ
donor program at Heidelberg University hospital whenever there
was no suitable recipient for organ transplantation (n=20). All
patients were informed, and written consent was obtained. The
studies were approved by the Ethics Committee of the University
of Heidelberg (Germany).
Immunohistochemistry of human pancreatic tissues
CB1- and CB2-receptors were localized in the human pancreas
using immunohistochemistry. Rabbit anti human-CB1 and anti
human-CB2 antibodies (Cayman Chemical, Ann Arbor, MI, USA)
were used at a dilution of 1:150 and 1:300, respectively. Specificity
was checked by performing pre-adsorption of the primary antibody
with the corresponding blocking peptide for 1 hour at 37uC.
Endocannabinoid level measurements
Levels of anandamide (AEA), 1-arachidonoylglycerol (1-AG)
and 2-arachidonoylglycerol (2-AG) in frozen human pancreas
samples (normal pancreas: n=6; chronic pancreatitis: n=6) were
determined by liquid chromatography/mass spectrometry as
described previously [35].
Reagents
Ham’s F12 medium, DMEM, trypsin-EDTA and penicillin-
streptomycin were purchased from Invitrogen (Karlsruhe, Ger-
many); amphotericin B 250 mg/ml was purchased from PAA
Laboratories (Pasching, Germany); fetal calf serum (FCS) was
purchased from PAN Biotech (Aidenbach, Germany); the
enhanced chemoluminescence (ECL) immunoblotting detection
reagents were obtained from Amersham Biosciences (Buckin-
ghamshire, UK); Mini EDTA-Free Protease inhibitor was
purchased from Roche Molecular Biochemicals (Basel, Switzer-
land); and the BCA protein assay was from Pierce Chemical Co.
(Rockford, IL, USA) and the MTT test reagent was purchased
from Sigma Aldrich (Taufkirchen, Germany).
Isolation of human pancreatic stellate cells
Human PSC isolation and culture were performed as described
by Bachem et al.[11] using the outgrowth method. For our
experiments, cell populations between passage 3 and 5 were used.
A 1:1 (vol/vol) mixture of low glucose (1000 mg/L) DMEM with
Ham’s F12 medium supplemented with 20% FCS, L-glutamine
(2 mM), penicillin/streptomycin, and amphotericin B was the
standard growth medium, whereas for pharmacology experiments,
1% FCS was used.
Immunocytochemistry
Immunocytochemistry was performed as described previous-
ly[36]. Cells were seeded in 20% FCS. Anti-CB1-receptor and
anti-CB2-receptor antibodies were diluted 1:300 in Antibody
Diluent (DakoCytomation, Hamburg, Germany). Specificity
controls included pre-adsorption of the primary antibody with
the corresponding blocking peptide (1:1) for 1 hour at 37uC.
Cannabinoid treatment and proliferation assays
PSC were plated on the bottom of 24-well plates at densities of
40,000/well in 500 ml DMEM/Ham’s F12 (1/1, v/v) in the presence
of 20% FCS for 24 hours. Subsequently, the medium was changed to
DMEM/Ham’s F12 with 1% FCS. After overnight incubation, drugs
were added at concentrations of 1.25, 2.5 and 5 mM. WIN55,212-2
(WIN; Tocris Cookson Ltd., Avonmouth, UK) was dissolved in
DMSOand furtherdiluted in ethanol(EtOH).SpecificCB1-receptor
and CB2-receptor antagonists (AM251 and AM630, respectively)
were dissolved in EtOH. Controls included DMSO/EtOH at a
dilution of 1:1000. After 48 hours of incubation, proliferation was
determined using MTT tests, as described previously[37]. These
experiments were repeated five times, whereas experiments for
determination of WIN-specificity (pre-incubation with AM251 and/
or AM630 before addition of WIN) were repeated twice. To exclude
that potential anti-proliferative effects of cannabinoids influenced
evaluation of cytokine and ECM protein secretion, treatment was
begun when the cells reached 100% confluency.
Apoptosis assays
Cells were grown to 70–80% confluency in medium containing
20% FCS before the FCS concentration was reduced to 1%. After
24 hours of incubation, drugs were added for another 24 hours, as
described for the proliferation assays. Single cell suspensions were
obtained using trypsin-EDTA. Subsequently, the Guava Nexin
TM
kit (Guava Technologies, Hayward, CA, USA) was used to
determine the number of early and late apoptotic cells according
to the manufacturer’s instructions.
LDH analysis
Lactate dehydrogenase (LDH) in cell culture supernatants was
measured in the central clinical laboratories at the University of
Heidelberg using an ADVIA2400 machine (Siemens, Erlangen,
Germany).
Invasion assay
Matrigel
TM-coated invasion chambers (BioCoat Matrigel Inva-
sion Chamber, BD Biosciences, Heidelberg, Germany) were
rehydrated for 2 hours in serum-free medium at 37uC and 5%
Cannabinoids in PSC
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medium at a concentration of 2.5610
4 cells per insert. 675 ml
serum-free medium was added to the inner wells. Cannabinoid
receptor antagonists AM251 and AM630, a combination of both,
or the respective controls were added to the wells and the inserts to
a final concentration of 2.5 mM. Following 30 min of incubation,
the synthetic cannabinoid agonist WIN55,212-2 was also added to
all wells and inserts (final concentration of 2.5 mM). At the end of
the 24-hour incubation period, supernatants were aspirated and
the upper part of the membrane was cleaned with cotton swabs.
Cells were then fixed with 75% methanol and 25% acetone for
30 minutes and subsequently stained with toluidine blue. The
inserts were rinsed in distilled water to remove excess stain.
Finally, the membranes were placed on glass slides and invaded
cells were counted.
Immunofluorescence assays
Immunofluorescence assays were performed as previously
described [38]. Briefly, 1610
4 PSC per well were seeded on
teflon
TM-coated slides (Erie Scientific Company, Portsmouth, NH,
USA) in 20% FCS-containing medium, and were incubated for
24 hours before the medium was changed to 1% FCS. Upon
further incubation for 24 hours, the cannabinoid agonist
WIN55,212-2, the CB1-receptor antagonist AM251, or the
CB2-receptor antagonist AM630 was added at a final concentra-
tion of 5 mM. After 48 hours, cells were fixed with 4%
paraformaldehyde, permeabilized with 1% Triton-X, and incu-
bated with phalloidin (1:500) for 20 minutes. To counterstain the
nuclei, DAPI stain was added at a 1:1000 dilution.
ELISA
To determine levels of MCP-1, IL-6 and TGF-beta in cell
culture supernatants, commercial solid phase sandwich ELISA kits
(BD OptEIA
TM, BD Biosciences, Heidelberg, Germany) were
used according to the manufacturer’s instructions. MMP-2 levels
were determined using an ELISA kit obtained from R&D Systems
(Minneapolis, MN, USA) according to the instructions of the
manufacturer.
Immunoblot analysis (ECM proteins)
For immunoblot analyses, cell culture supernatants or cell
lysates (cells treated with 2.5 mM of WIN, AM251 and/or AM630;
or WIN (2.5 mM)+/2AM251/AM630 (5 mM) as indicated in
‘‘proliferation assays’’) were processed as described [38]. Cells
were grown to reach 100% confluency before initiation of
treatment to exclude effects on proliferation. Supernatants and
cell lysates from three independent experiments were pooled prior
to SDS-PAGE. Primary antibodies for collagen type-1 (diluted
1:200; sc-28657, Santa Cruz biotechnology, Santa Cruz, CA,
USA), fibronectin (1:10,000; F3648, Sigma Aldrich, Taufkirchen,
Germany), alphaSMA (1:10,000, M0851, DAKO Cytomation,
Hamburg, Germany) and gamma-tubulin (1:5,000; sc-7396, Santa
Cruz biotechnology) were applied overnight at 4uC; secondary
antibodies (diluted correspondingly 1:2,000, 1:5,000, 1:5,000,
1:5,000) were added for one hour at room temperature.
Densitometry was performed as described previously [38].
Statistical analysis
Statistical analysis and graph presentation were performed using
GraphPad Prism 4 Software (GraphPad, San Diego, CA, USA).
For comparisons of the control group versus antagonist groups,
one-way analysis of variance (ANOVA) for random measures was
applied, followed by Bonferroni’s post-hoc test. For comparisons of
control PSC versus WIN-treated PSC, a paired t-test was used.
ANOVA (and Bonferroni’s post-hoc test) was used to compare
WIN-treated PSC versus CB-receptor antagonist pre-treated
groups. The level of statistical significance was set at p,0.05.
Results
Regulation of CB1, CB2 and endocannabinoids in normal
pancreas and chronic pancreatitis
In chronic pancreatitis tissue samples, various staining patterns
were present. In tubular complexes which result from metaplasia
of acinar cells to duct-like structures, weak immunoreactivity was
seen for CB1 (Figure 1A), whereas moderate to strong stainings
were observed for CB2 (Figure 2A). Weak immunoreactivity for
CB1 in nerves (Figure 1D) was observed in 13 tissue samples,
moderate staining in 21 samples, and strong immunostaining in 8
samples (Figure 1C). Immune cell infiltrates were only faintly
stained with CB1 (Figure 1B), whereas for CB2, only weak
immunoreactivity was seen in nerves (Figure 2B). However,
immune cell infiltrates were CB2-positive: in 11 samples there was
weak staining (Figure 2B), 18 samples were moderately immuno-
positive, and 13 samples were strongly stained. Pancreatic stellate
cells in areas of fibrosis were also immunopositive for CB1 and
CB2 (Figures 1E and 2C). Immunohistochemistry of normal
human pancreatic tissues revealed weak immunoreactivity for CB1
and CB2 in pancreatic acini, nerves, blood vessels and ductal cells,
as previously described (lower insets Figures 1A & 2A;[39]).
We then assessed the levels of endocannabinoids in chronic
pancreatitis. In contrast to the findings in acute pancreatitis, where
upregulation of endocannabinoids was observed [39], levels of
anandamide were decreased 2.2-fold in chronic pancreatitis
(statistically not significant, p=0.14; Figure 2D) and 1+2-AG
levels were reduced 4.2-fold (p=0.0066; Figure 2D).
Cannabinoid receptors are expressed on pancreatic
stellate cells
Immunocytochemistry revealed that both CB1- and CB2-
receptors are present on pancreatic stellate cells (Figures 1F & 2E).
While CB1 showed a dotted expression pattern with strong
staining intensity (Figure 1F), CB2 immunostaining was less
intensely distributed within the stellate cells (Figure 2E).
Functional significance of the endocannabinoid system
in chronic pancreatitis
To evaluate the functional relevance of decreased endocanna-
binoid release and upregulation of cannabinoid receptors in
human chronic pancreatitis, CB1 and CB2 receptors were blocked
on pancreatic stellate cells (the major contributors of extracellular
matrix protein production; all antagonist results from three
independently performed experiments) which had been isolated
from human chronic pancreatitis tissues. AM251 and AM630
were used as specific antagonists to CB1 and CB2 receptors,
respectively. Effects of antagonist treatment on stellate cell
proliferation were assessed using MTT tests: both AM630 and
AM251 did not influence proliferation of PSC at the tested
concentrations of 1.25, 2.5 and 5 mM( p .0.05, respectively, as
tested by ANOVA and post-hoc Bonferroni’s test; Figure 3A).
Potential effects of cannabinoid receptor antagonism on either
necrosis or apoptosis were determined by analyzing levels of
lactate dehydrogenase (LDH) in cell culture supernatants and by
performing the Guava Nexin
TM apoptosis test on AM251- and
AM630-treated PSC. These experiments revealed that AM251
and AM630 induced neither necrotic cell death—as judged by
unchanged LDH levels—nor apoptosis (Figures 3B). Further
Cannabinoids in PSC
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1701Figure 2. Cannabinoid receptor 2 and endocannabinoid levels in chronic pancreatitis. Using an anti-CB2 antibody, tubular complexes
were strongly stained (A). Invading mononuclear cells were also immunopositive (B), whereas intrapancreatic nerves were mostly unstained or only
faintly positive (B). Pancreatic stellate cells were immunopositive for CB2 (C). The endocannabinoids anandamide (AEA) and 1+2-arachidonoylglycerol
(1+2-AG) were lower in chronic pancreatitis (AEA: p=0.14 and 1+2-AG: p=0.0066; D). Cultured pancreatic stellate cells were faintly CB2-
immunopositive (E). Original magnification: x20 (A, B), x40 (C), x80 (F). Insets: negative controls. Lower insets (A): CB2 in normal pancreas.
doi:10.1371/journal.pone.0001701.g002
Figure 1. Cannabinoid receptor 1 in human chronic pancreatitis tissues. CB1 immunohistochemistry: staining of tubular complexes (A) but
immunonegativity of infiltrating mononuclear cells (B); various staining intensities of intrapancreatic nerves (C&D); pancreatic stellate cells in areas of
fibrosis (E) or isolated and cultured in vitro (F). Original magnification: x20 (A, B, D), x40 (C), x80 (F). Insets: negative controls. Lower insets (A): CB1 in
normal pancreas.
doi:10.1371/journal.pone.0001701.g001
Cannabinoids in PSC
PLoS ONE | www.plosone.org 4 February 2008 | Volume 3 | Issue 2 | e1701Figure 3. Effects of cannabinoid receptor antagonism on pancreatic stellate cells. (A) MTT assays after 48 hours’ incubation of PSC with
graded concentrations of CB1- and CB2-receptor antagonists AM251 and AM630 (p=n.s. for concentrations of 1.25, 2.5 and 5 mM). (B) LDH in cell
culture supernatants and the fraction of apoptotic cells as judged by the GuavaNexin
TM test. AM251 significantly increased IL-6 (C) but decreased
MCP-1 secretion (D); AM630 had no effect on IL-6 (C) but induced a tendency towards increased MCP-1 levels (D). CB1-/2-receptor antagonism did
not affect TGFbeta (E). Data are shown as mean6SEM (*, p,0.05).
doi:10.1371/journal.pone.0001701.g003
Cannabinoids in PSC
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and antagonist groups) showed that there was no difference in the
number of early and late stage apoptotic cells, as well (not shown).
To further assess functional consequences of endocannabinoid
blockade in PSC, production of cytokines IL-6 and TGFbeta,
chemokine MCP-1 and ECM proteins collagen1 and fibronectin
was analyzed. While AM251 significantly induced IL-6 secretion
at a concentration of 5 mM( p ,0.05, ANOVA; Figure 3C), an
inverse effect was observed regarding MCP-1, with AM251
decreasing its levels in cell culture supernatants (p,0.05, ANOVA;
Figure 3D). AM630 did not influence IL-6 levels; however, there
was a trend toward increased MCP-1 secretion (Figure 3C&D).
In a next step, the profibrogenic cytokine TGFbeta, which
stimulates the synthesis and secretion of fibronectin, collagen1 and
matrix metalloproteinases, was analyzed, revealing that neither
AM251 nor AM630 significantly altered secreted TGFbeta levels
(Figure 3E). Furthermore, AM215 had no effects on fibronectin
and collagen 1 secretion (cell culture supernatants of cells grown to
100% confluency before initiation of treatment; immunoblots from
three pooled experiments; Figure 4). Blockade of the CB2-receptor
by AM630 did also not change collagen 1 and fibronectin
production (Figure 4). However, AM630 induced an increase of
alphaSMA protein levels (pooled cell lysates from three indepen-
dently performed experiments; Figure 4).
Evaluation of invasiveness as another key feature of pancreatic
stellate cells was carried out using Matrigel
TM-coated cell culture
inserts, as previously described[38]. Although there was a
tendency toward an increased number of invaded cells treated
with AM251 (p=n.s.; mean increase compared with control:
+47%; Figure 5A), MMP-2 levels in cell culture supernatants were
not different from the control treatment group (Figure 5B).
However, there were distinct changes in stellate cell morphology
after incubation with the CB1-receptor antagonist AM251, as
judged by actin cytoskeleton staining (Figure 5C&D; control PSC:
inserts), whereas AM630-treated PSC closely resembled the
control cell phenotype (Figure 5E&F). Treatment of PSC with
AM251 induced a thinner, more stretched shape in the cells, with
an increased length but an overall smaller size (Figure 5 C&D).
Additionally, we observed a marked loss of intracellular fibres
upon incubation with AM251. These results are supported by a
recent publication which reports on an association between loss of
actin polymerization and increased invasiveness [40].
Cannabinoid receptor activation reduces markers of
inflammation and fibrosis in PSC
In an approach to reduce the overt activity of stellate cells
present in chronic pancreatitis through augmentation of the down-
regulated endocannabinoid system, we treated PSC with the
synthetic cannabinoid receptor agonist WIN55,212-2 (WIN; all
results from three independently performed experiments). Canna-
binoid receptor selectivity of the effects of WIN on PSC was
evaluated by pre-incubation with the respective antagonists at the
cannabinoid-1 and -2 receptors and with a combination of both.
As shown by MTT assays, WIN dose-dependently decreased
proliferation of PSC (p,0.05 for concentrations of 2.5 mM and
5 mM, respectively, ANOVA), which was partially reversible by
pre-incubation with a combination of the CB1- and CB-2-receptor
antagonists AM251 and AM630 (Figure 6A–D), but not by the
respective receptor antagonists alone (Figure 6B&D). To evaluate
whether this effect was due to induction of apoptosis or necrosis,
lactate dehydrogenase was analyzed in cell culture supernatants
and a GuavaNexin
TM test was performed. These experiments
revealed that the growth-inhibitory effects of WIN were not due to
necrotic cell death, as shown by unchanged LDH levels following
WIN treatment with/without pre-incubation with the CB1/2-
receptor antagonists (Figure 6E). Similarly, we observed no
induction of apoptosis (Figure 6E), either at an early or a late
stage (not shown).
To assess the effects of WIN treatment of PSC on the secretion of
cytokines IL-6, MCP-1 and TGFbeta, cell culture supernatants were
subjected to ELISA. These experiments demonstrated that IL-6 and
MCP-1 secretion were significantly reduced by WIN (p=0.001 and
p=0.0002, respectively; Figure 7A). Preincubation with a combi-
nation of AM251 and AM630 (5 mM, respectively) partially reversed
this effect (Figure 7A). In contrast, there was a trend toward
increased TGFbeta levels (increase by 42%; Figure 7B) which was
nearly absent when cells had been pre-treated with a combination of
AM251 and AM630 (increase by only 8%; Figure 7B). Immunoblot
analysis of cell culture supernatants showed significantly reduced
fibronectin and collagen 1 levels after WIN treatment (supernatants
of PSC grown to 100% confluency before initiation of treatment;
Figure 7B). Pre-incubation with AM251 and/or AM630 (5 mM)
revealed that the suppressive effect of WIN on fibronectin and
collagen 1 production was partially reversible only when using both
antagonists concomitantly (Figure 7B; pooled cell culture super-
natanty from three independently performed experiments). Further-
more, WIN induced a reduction in alphaSMA levels which was also
partially reversed by pre-incubation with a combination of both CB-
receptor antagonists (Figure 7B; equal loading: gamma-tubulin).
Cannabinoids decrease invasiveness of PSC and
downregulate MMP-2
As with CB receptor antagonists alone, invasiveness of PSC
following treatment with WIN (+/2 pre-incubation with AM251
and/or AM630) was analyzed using Matrigel
TM invasion chambers
(resultsfromfourindependent experimentswhich wereperformed in
duplicates). WIN significantly reduced the number of invaded cells
(p=0.0081; Figure 8A), whereas pre-incubation with AM251 or a
Figure 4. Cannabinoid receptor blockade alters synthesis of
ECM proteins. As assessed by immunoblot analysis of cell culture
supernatants, AM251 and AM630 (at 2.5 mM) did not affect collagen
and fibronection secretion. In PSC cell lysates, alphaSMA levels remain
unchanged following CB1-receptor antagonism whereas AM630
induced increased alphaSMA protein levels. White bars: control; black
bars: AM251; grey bars: AM630. Data are shown as mean6SEM.
doi:10.1371/journal.pone.0001701.g004
Cannabinoids in PSC
PLoS ONE | www.plosone.org 6 February 2008 | Volume 3 | Issue 2 | e1701Figure 5. AM251 induces changes in PSC phenotype. (A) Invasion assays demonstrated a trend toward increased invasiveness induced by
AM251. (B) MMP-2 levels were unchanged by antagonist treatment. (C&D) AM251-treated pancreatic stellate cells were smaller and thinner, with a
more stretched shape, an increased length, and a loss of intracellular fibres (control PSC: insets and Figure 8C&D). Cells treated with AM630 (E&F)
closely resembled the control PSC (see insets C&D and Figure 8C&D). Original magnification: x 40 (C&E), x 80 (D&F). Nuclear stain: DAPI. White bars:
control; black bars: AM251; grey bars: AM630. Data are shown as mean6SEM.
doi:10.1371/journal.pone.0001701.g005
Cannabinoids in PSC
PLoS ONE | www.plosone.org 7 February 2008 | Volume 3 | Issue 2 | e1701Figure 6. Cannabinoid receptor activation on PSC reduces growth, independent of apoptosis or necrosis. (A) MTT tests of WIN-treated
PSC revealed dose-dependent inhibition of growth (p,0.05 at concentrations of 2.5 and 5 mM). (B&C) While AM251 and AM630 alone were not
effective, pre-treatment with a combination of AM251 and AM630 blocked WIN-induced growth inhibition (D). The reduction in proliferated cells was
neither due to necrosis (unchanged LDH levels) nor to apoptosis (constant low number of apoptotic cells in treated versus control PSC; E). Data are
shown as mean6SEM (* p,0.05).
doi:10.1371/journal.pone.0001701.g006
Cannabinoids in PSC
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(5 mM, respectively; Figure 8A). Pre-treatment with AM630 showed
no differences from treatment with WIN alone (Figure 8A).
To evaluate whether the WIN-induced reduction in invasive-
ness was due to decreased levels of matrix metalloproteinase 2, cell
culture supernatants were analyzed by ELISA after WIN
treatment (+/2 pre-incubation with AM251/AM630, 10 mM).
We observed a significant decrease of MMP-2 levels after
treatment with WIN (p=0.026; Figure 8B) which was specifically
reversible using a combination of both antagonists (to .50% of
control cell culture supernatants).
Analysis of the PSC morphology after treatment with WIN (as
shown by actin cytoskeleton immunofluorescence) demonstrated
distinct changes: whereas cell morphology was unchanged in
control PSC (Figure 8C&D), WIN induced a more round-shaped
phenotype, with a reduction in cellular extensions (Figure 8E&F).
We also observed a loss of intracellular fibres, accompanied by a
disorganization of these fibres and a generally smaller PSC
phenotype. Furthermore, the number of cell-cell contacts tended
to be lower after treatment with WIN (Figure 8E).
Discussion
In the present study, we show that activation of the
endocannabinoid system in chronic pancreatitis-derived stellate
cells specifically induced a more quiescent phenotype, accompa-
nied by suppression of pro-inflammatory cytokines and extracel-
lular matrix proteins as well as a decrease in invasiveness of PSC.
The loss of functional pancreatic parenchyma, which is substituted
by a fibrotic scar with massive infiltration of lymphocytes, is
Figure 7. WIN de-activates pancreatic stellate cells. (A) IL-6 and MCP-1 secretion were significantly reduced by WIN (p=0.001 and p=0.0002,
respectively), independent of TGFbeta (B; unchanged TGFbeta levels). The reduction in IL-6 and MCP-1 levels was partially reversed by a combination
of the CB1-receptor and CB2-receptor antagonists AM251 and AM630 (A). While control PSC secreted significant amounts of fibronectin and collagen
1 (as seen by an intense signal at 220 and 190 kDa, respectively), treatment with WIN reduced the signal at the respective molecular weights (B;
immunoblots of cell culture supernatants, pooled from three independent experiments). AlphaSMA levels were also suppressed by WIN (B;
immunoblot of PSC cell lysates; gamma-tubulin: equal loading control). A combination of both antagonists AM251 and AM630 partially reversed the
suppressive effects elicited by incubation with WIN (B, immunoblots of fibronectin, collagen 1 and alphaSMA). White bars: control; black bars:
WIN55,212-26AM251/AM630. Data are shown as mean6SEM.
doi:10.1371/journal.pone.0001701.g007
Cannabinoids in PSC
PLoS ONE | www.plosone.org 9 February 2008 | Volume 3 | Issue 2 | e1701Figure 8. Cannabinoid receptor activation reduces invasiveness. A significant reduction in the number of invaded cells was seen after
treatment with WIN (p=0.0081; A). A near-complete reversal of the reduced invasiveness was seen when the cells were pre-incubated with AM251 or
a combination of AM251 and AM630 (A). This was not found with AM630 alone (A). WIN induced a significant decrease in MMP-2 levels (p=0.026; B)
which was partially reversible by a combination of AM251 and AM630 (B). Actin cytoskeleton staining with phalloidin demonstrated that control PSC
showed the normal cellular structure (C&D) but that WIN induced a more round and smaller PSC phenotype (E&F). Original magnification: x 40 (C&E),
x 80 (D&F). Nuclear stain: DAPI. White bars: control; black bars: WIN55,212-26AM251/AM630. Data are shown as mean6SEM.
doi:10.1371/journal.pone.0001701.g008
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no treatment available for controlling the excessive activation of
pancreatic stellate cells, which mainly produce the extracellular
matrix and which activate themselves in an autocrine loop by
secreting pro-fibrogenic molecules such as TGFbeta and by
producing pro-inflammatory cytokines.
The most important finding of this study is that cannabinoid
receptor activation induces a quiescent phenotype of chronic
pancreatitis-derived PSC by downregulating production of extracel-
lular matrix proteins and inflammatory cytokines. This effect was
accompanied by marked changes in PSC appearance toward a less
mesenchymal-like phenotype. Since migration of PSC to sites of
damage can induce either re-differentiation of PSC and tissue repair
orsupportactivation and fibrosis,weevaluated theinvasivepotential
as a factor contributing to PSC motility[12,13,41,42]. We observed
that suppression of PSC invasiveness by unselective CB receptor
activation was accompanied by decreased MMP-2 levels. This could
be particularly important not only in terms of invasiveness but also
for influencing the distorted balance of matrix synthesis and
degradation, since it is known that increased levels of MMP-2 (not
only in chronic pancreatitis) facilitate the deposition of pathological
fibrillar collagen[12,43]. Furthermore, it has been suggested for both
pancreatic and hepatic stellate cells that MMP-2 may have effects on
proliferation. Thus, cannabinoid-induced suppression of MMP-2
could be a mediator of the induction of a more quiescent phenotype,
leading to reduced collagen synthesis.
Furthermore, there are a number of regulators of PSC
activation: 1) paracrine factors such as cytokines (IL-1, MCP-1),
growth factors (TGFbeta and PDGF) and endothelium-derived
substances (endothelin-1) which are released by recruited inflam-
matory cells; and 2) factors secreted by destroyed parenchymal
cells, such as acinar, endothelial and ductal cells [14,15,44–46].
PSC can also perpetuate their activation by producing autocrine
mediators such as IL-6, TGFbeta, PDGF or the most recently
discovered periostin [38]. Once activated, PSC recruit and
stimulate leukocytes via MCP-1 and IL-8. In our experimental
setup, we chose to analyze MCP-1 levels upon blockade or
augmentation of the endocannabinoid system with synthetic
cannabinoids. Here, significantly reduced levels of MCP-1 and
IL-6 were observed, suggesting interference of cannabinoids in the
autocrine loop, with the effect of de-sensitization of excessively
stimulated pancreatic stellate cells. These results are supported by
the observation that the endocannabinoid system is suppressed in
chronic pancreatitis, which is particularly important since chronic
pancreatitis—in contrast to liver cirrhosis—is usually associated
with a severe pain syndrome. Thus, down-regulation of pain-
inhibitory endocannabinoids could participate in pain generation
in chronic pancreatitis. In concordance with the contradictory
results of cannabinoid receptor activation and antagonism in
hepatic stellate cells, blockade of the remaining ECS activity
exerted at least some beneficial effects, such as suppression of the
chemokine MCP-1 which may be explained by increased
endocannabinoid secretion upon blocking the receptors. However,
we also observed that cannabinoid receptor-1 antagonism induced
production of the pro-inflammatory cytokine IL-6 and induced a
more motile PSC phenotype, as judged by a trend toward
increased invasiveness and a longitudinally stretched appearance.
For liver cirrhosis it has recently been shown that CB2-receptor
activation mediated anti-fibrosis by apoptosis induction and
growth inhibition of hepatic stellate cells [33]. In our study,
antagonism of cannabinoid receptor-2 elicited no such effects.
Because drugs for the treatment of chronic pancreatitis should
ideally exert anti-fibrotic and anti-inflammatory properties, their
bimodal effects rather contradict a therapeutic use of CB-receptor
antagonists and promote the hypothesis that (re-)activation of the
(endo-)cannabinoid system in chronic pancreatitis may be
beneficial for suppressing disease progress. This holds particularly
true since the suppressive effects induced by the cannabinoid
receptor agonist WIN55212,2 were reversible by pre-incubation
with a combination of CB1- and CB2 receptor antagonists AM251
and AM630. Though CB1 receptors constitute the ‘‘main primary
antinociceptive targets for systemically- or peripherally-applied
cannabinoids in vivo’’ [47], activation of central CB1 receptors
also dose-dependently induces side-effects such as hindrance of
activity, motor dysfunction, sedation or catalepsy [47–49]. Thus, a
major challenge for the clinical use of cannabinoids, i.e. as an anti-
fibrogenic therapy, will be the reduction of these cognitive,
affective and motor function side-effects [47,50]. An alternative to
selective, peripheral cannabinoid receptor agonists might be the
manipulation of endocannabinoid metabolism by blockade of
endocannabinoid degradation or uptake [50,51]. This approach
could be particularly advantageous in chronic pancreatitis where
the endocannabinoid system is locally suppressed and where this
pathological state could thus be reversed. However, future studies
are needed to pinpoint the precise mechanisms of cannabinoid-
induced de-activation of pancreatic stellate cells and particularly its
effects in vivo: 1) in a disease-prevention model, 2) in an approach
to slow down the destruction of functional pancreatic parenchyma,
and 3) in their potency to reverse fibrosis.
In conclusion, we show that the endocannabinoid system is
downregulated in chronic pancreatitis and that its augmentation
via exogenously administered cannabinoids specifically reduces
activation of pancreatic stellate cells. These experiments lay a basis
for testing the value of synthetic cannabinoids in the treatment of
chronic pancreatitis.
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